ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 0718

Incidence and Patient Profile Changes in ANCA-Associated Vasculitis Following the SARS-CoV-2 Pandemic

Laura Ramos Ortiz de Zarate1, Aresio Plaza Lopez2, Alejandro mARTINEZ rODADO3, Maria Machattou1, Pablo Navarro Palomo4, maria alonso de francisco3, Carlota Navarro Joven3, Natalia de la Torre-Rubio4, Olga Rusinovich5, Carolina Merino6, Blanca García Magallón7, Jose Campos Esteban7, hildegarda Godoy Tundidor8, Mónica Fernández Castro9, JESUS SANZ SANZ4, Carmen Barbadillo Mateos7, Carlos Maria Isasi Zaragoza7, Andrea Liso Andrino7, Maria Concepcion Sanchez Fernandez3 and Jose Luis Andreu4, 1Hospital Universitario Puerta de Hierro Majadahonda., Madrid, Spain, 2Hospital Puerta de Hierro Majadahonda, Madrid, Spain, 3Hospital Universitario Puerta de Hierro Majadahonda., Majadahonda, Madrid, Spain, 4Hospital Universitario Puerta de Hierro Majadahonda., Majadahonda, Spain, 5Hospital Universitario Puerta de Hierro Majadahonda., Boadilla del Monte, Spain, 6Hospital Universitario Puerta de Hierro Majadahonda., Majadahonda (Madrid), Spain, 7Servicio de Reumatología, Hospital Universitario Puerta de Hierro Majadahonda, IDIPHISA , Madrid, Majadahonda, Madrid, Spain, 8Servicio de Reumatología, Hospital Universitario Puerta de Hierro Majadahonda, IDIPHISA , Madrid, Madrid, Spain, 9Hospital Universitario Puerta de Hierro Majadahonda., Madrid, Madrid, Spain

Meeting: ACR Convergence 2024

Keywords: ANCA, ANCA associated vasculitis, Comorbidity, COVID-19

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Saturday, November 16, 2024

Title: Vasculitis – ANCA-Associated Poster I

Session Type: Poster Session A

Session Time: 10:30AM-12:30PM

Background/Purpose: Antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis is often linked to previous viral infections. Clinical evidence suggests SARS-CoV-2 virus may follow a similar pattern, with an observed post-pandemic increase in autoimmune disease incidence and flares attributed both to infection and vaccination. This study aims to compare the incidence of vasculitis following ANCA seroconversion before (2019) and after the pandemic onset (2021) and to evaluate whether the profile of patients changed following the SARS-CoV-2 pandemic.

Methods: This retrospective study collected positive ANCA records (ANCAc, ANCAp, anti-MPO, anti-PR3) from 2019 and 2021, reviewing clinical records for the following 2 years or until a vasculitis diagnosis. Included patients had no prior vasculitis diagnosis and had not previously tested positive for the same ANCA, although they could have tested positive for a different antibody. Patients lost to follow-up or who passed away before the 2 year mark without a vasculitis diagnosis were excluded. Data on comorbidities was collected and analyzed using descriptive and inferential statistics.

Results: A total of 380 ANCA-positive records from 138 patients were obtained. 51 patients had previous positive results. 48 had ANCA seroconversion in 2019 (group A), 2 of whom had a second seroconversion with a different antibody in 2021. 39 patients had their first seroconversion in 2021 (group B), along with the two patients who seroconverted both in 2019 and 2021.

Both group A and group B patients had similar comorbidities, with significant differences in the prevalence of previous rheumatological diseases at the time of ANCA seroconversion (p=0.032), 19% in Group A and 39% in Group B. Descriptive analysis showed differences in smoking (42% Group A vs. 22% Group B) and respiratory pathology (38% Group A vs. 20% Group B). Incidence in vasculitis in both groups was similar. Patients who developed vasculitis showed significant differences from those who did not, related to smoking (p=0.004) and previous respiratory pathology (p = 0.005) in both the general cohort and Group A (32.5% smokers in non-vasculitic group vs 100% smokers in vasculitic one). No significant difference in smoking was found in Group B (25% smokers in non-vasculitic group vs. 50% in vasculitic group). A trend towards lower previous respiratory pathology was noted in Group B (25% vs. 80% in Group A) and lower hypothyroidism prevalence (0% in Group B vs. 40% in Group A). In patients who did not develop vasculitis, Group B showed a significantly lower prevalence of ENT pathology at 3% vs. 20% in Group A (p = 0.031). None of the 15 patients with chronic infections (HIV, HCV, Chagas disease) or tumors developed vasculitis. After ANCA seroconversion, 22% of patients in 2019 and 17% in 2021 were diagnosed with a rheumatological, non-ANCA-vasculitis pathology.

Conclusion: Patients who seroconverted for ANCA in 2021 tended to smoke less, have more previous rheumatological pathologies, less previous respiratory pathology, and lower hypothyroidism prevalence. These results highlight the need for further research on the long-term effects of SARS-CoV-2 infection and vaccination on autoimmune conditions such as ANCA-associated vasculitis.


Disclosures: L. Ramos Ortiz de Zarate: None; A. Plaza Lopez: None; A. mARTINEZ rODADO: None; M. Machattou: None; P. Navarro Palomo: None; m. alonso de francisco: None; C. Navarro Joven: None; N. de la Torre-Rubio: None; O. Rusinovich: None; C. Merino: None; B. García Magallón: None; J. Campos Esteban: None; h. Godoy Tundidor: None; M. Fernández Castro: None; J. SANZ SANZ: None; C. Barbadillo Mateos: None; C. Isasi Zaragoza: None; A. Liso Andrino: None; M. Sanchez Fernandez: None; J. Andreu: None.

To cite this abstract in AMA style:

Ramos Ortiz de Zarate L, Plaza Lopez A, mARTINEZ rODADO A, Machattou M, Navarro Palomo P, alonso de francisco m, Navarro Joven C, de la Torre-Rubio N, Rusinovich O, Merino C, García Magallón B, Campos Esteban J, Godoy Tundidor h, Fernández Castro M, SANZ SANZ J, Barbadillo Mateos C, Isasi Zaragoza C, Liso Andrino A, Sanchez Fernandez M, Andreu J. Incidence and Patient Profile Changes in ANCA-Associated Vasculitis Following the SARS-CoV-2 Pandemic [abstract]. Arthritis Rheumatol. 2024; 76 (suppl 9). https://acrabstracts.org/abstract/incidence-and-patient-profile-changes-in-anca-associated-vasculitis-following-the-sars-cov-2-pandemic/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2024

ACR Meeting Abstracts - https://acrabstracts.org/abstract/incidence-and-patient-profile-changes-in-anca-associated-vasculitis-following-the-sars-cov-2-pandemic/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology